Select the search type
  • Site
  • Web

HPV Testing and Vaccination

HPV Primary Screening: Expert Panel Resources

The National Screening Unit (NSU) hosted an Expert Panel on HPV Primary Screening in Auckland and Christchurch this year.

To view the presentations click on the speakers below:

Dr Jane O’Hallahan, Clinical Director National Screening Unit - Benefits and harms of screening

Dr Karen Canfell, Director of Research, Cancer Research Division, Cancer Council NSW - The science behind NZ’s decision to change to Primary HPV Testing

Dr Marion Saville, Chairperson HPV Testing for Primary Screening Project - Compass trial leading the way

Dr Margaret Sage, Clinical Leader Pathology, National Cervical Screening Programme - The ARTISTIC trial (UK). Putting invasive cancer in perspective 

Dr Gary Fentiman, Clinical Leader Colposcopy, National Cervical Screening Programme - Responding to your concerns

HPV infection and vaccination review

Click on the link below for the latest HPV research review

Educational Series - Human Papilloma Virus Infection and Vaccination.pdf

New Ministry of Health Video - The Story of HPV

This is a fantastic resource which explains the relationship between HPV vaccination and Cervical Screening

Click here for link to video

Free HPV Immunisation online course - Immunisation Advisory Centre

Click Here 

HPV testing free online course - Ministry of Health

Click Here

 HPV Primary Testing and Vaccination Powerpoint Presentations

(MACSAG Meeting 4th June 2015):

Primary HPV Overview and HPV Self-testing - Dr Karen Bartholomew, Public Health Physician Waitemata DHB

Primary HPV Evidence and Overseas Changes - Dr Lois Eva, Gynaecologist and Oncologist Auckland DHB

HPV Vaccination - Lisbeth Alley, Immunisation Education Facilitator IMAC

Update on the Compass Trial - Dr Mee Ling Yeung


HPV Vaccination: Current situation

The target for 2016 is 65% of eligible females to have had the three doses.  At present the overall coverage is well below that, but our most vulnerable young women are also the ones who have the best levels of protection.

The human papillomavirus (HPV) vaccine was added to the national immunisation schedule in 2008 for females aged 12 years.The vaccine is funded for females aged between 12 and 20 years. So far, uptake of the school-based vaccination programme has been lower than expected, therefore primary health care providers are encouraged to offer information, address any fears or concerns and promote uptake of the vaccine. Although not funded, the vaccine can also be given to males and older females.

Regular cervical screening, as part of the national screening programme, is still required for females who have received the HPV vaccine.

Research findings imply that the current HPV vaccination program in New Zealand, which involves delivery of a vaccine against HPV types 16/18, could prevent up to 62% of high grade lesions (53% of CIN 2 and 66% of CIN 3+). See:"Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand" (2013) Leonardo M Simonell, Hazel Lewis  Megan Smith, Harold Neal, Collette Bromhead 


By 2014 birth cohorts from 1990 to 2000 have been offered three doses of HPV vaccine. 

The chart below shows trends in uptake for Auckland Region for Maori, Pacific and "European and Other" ethnicities:

** Other includes all ethnicities except Maori or Pacific

National Women's Health
Phone: 09 307 4949
© 2010 Auckland District Health Board
Website Design and Development by NetPotential